Prognosis
Teva, Drugmakers in Talks With U.S. to End Generics Probes
- Deferred prosecution agreements among resolutions discussed
- Long-running price-fixing probe closely watched by Congress
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. and other generic drugmakers have held talks with the U.S. Justice Department in the past six months about resolving a long-running criminal antitrust probe of alleged price-fixing by the companies, according to people familiar with the matter.
Among the possible outcomes that have been discussed are deferred prosecution agreements in which the companies would admit to certain allegations but would be shielded from indictment in exchange for cooperating with the investigation and paying fines.